DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Pagibaximab
Pagibaximab
WO 2015/028850 Al 5 March 2015 (05.03.2015) P O P C T
Modifications to the Harmonized Tariff Schedule of the United States To
Prevention of Nosocomial Infections in Neonatal Intensive Care Units
Pharmaceutical Appendix to the Tariff Schedule 2
Using Phage Display to Select Peptides Binding to Type 8 Capsular Polysaccharide of Staphylococcus Aureus
WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
Staphylococcal Manipulation of Host Immune Responses
(INN) for Biological and Biotechnological Substances
Oral Presentations
INN Working Document 05.179 Update 2011
WO 2017/176762 Al 12 October 2017 (12.10.2017) P O P C T
International Nonproprietary Names (Inn) for Biological and Biotechnological Substances
(INN) for Biological and Biotechnological Substances
WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
GUIDANCE on the USE of INTERNATIONAL NONPROPRIETARY NAMES (Inns) for PHARMACEUTICAL SUBSTANCES
VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1- Exposed Infants
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Public Summary of Opinion on Orphan Designation for Pagibaximab for The
Top View
WO 2U11/1 7921 a L
Assessment of the Evolution of Cancer Treatment Therapies
T Cell Immunity and the Quest for Protective Vaccines Against Staphylococcus Aureus Infection
WO 2016/197071 Al 8 December 2016 (08.12.2016) P O P CT
Tim Malawi Mai Multe
Vaccine Monoclonal Antibody-Based Therapies for Microbial Diseases
Antibody-Based Therapy to Combat Staphylococcus Aureus Infections
Qualifying Therapeutic Discovery Project Grants
Bioworld Looks at 65 Innovative New Companies Special Report Bioworld Page 2 of 121
Exebacase for Patients with Staphylococcus Aureus Bloodstream Infection and Endocarditis
A Scientific Roadmap for Antibiotic Discovery
Monoclonal Antibodies Targeting Clostridium Difficile Licensed to Merck
Prevention and Treatment of Neonatal Nosocomial Infections Jayashree Ramasethu
(INN) for Biological and Biotechnological Substances
Exebacase for Staphylococcus Aureus Bloodstream Infection and Endocarditis
The Search for an Effective Staphylococcus Aureus Vaccine
Targeted Therapeutic Strategies in the Battle Against Pathogenic Bacteria
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Isolation of Highly Active Monoclonal Antibodies Against Multiresistant Gram- Positive Bacteria
WO 2014/108198 Al 17 July 2014 (17.07.2014) P O P C T
Fighting Bacterial Infections—Future Treatment Optionsଝ